Evidence map›Paper›PMID 25383074›Full record

ArticleCurrent psychiatry reviews2014

The Future of D-Cycloserine and Other Cognitive Modifiers in Obsessive-Compulsive and Related Disorders.

Michael L Sulkowski, Daniel A Geller, Adam B Lewin, Tanya K Murphy, Andrew Mittelman, Ashley Brown, Eric A Storch

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current psychiatry reviews, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Michael L SulkowskiUniversity of Arizona, Box 210069 Tucson, AZ 85721-0069.
Daniel A GellerMassachusetts General Hospital, Department of Psychiatry, 55 Fruit Street, Boston, MA 02114, .
Adam B LewinUniversity of South Florida, Department of Pediatrics, 880 6th Street South, Suite 460, Box 7523, St. Petersburg, FL 33701, .
Tanya K MurphyUniversity of South Florida, Department of Pediatrics, 880 6th Street South, Suite 460, Box 7523, St. Petersburg, FL 33701, , ; Universitry of South Florida, Department of Psychiatry, 880 6th Street South, Suite 460, Box 7523, St. Petersburg, FL 33701, Phone: (727) 767-8230, Fax: (727) 767-7786.
Andrew MittelmanMassachusetts General Hospital, Department of Psychiatry, 55 Fruit Street, Boston, MA 02114, .
Ashley BrownMassachusetts General Hospital, Department of Psychiatry, 55 Fruit Street, Boston, MA 02114, .
Eric A StorchUniversity of South Florida, Department of Pediatrics, 880 6th Street South, Suite 460, Box 7523, St. Petersburg, FL 33701, , ; Universitry of South Florida, Department of Psychiatry, 880 6th Street South, Suite 460, Box 7523, St. Petersburg, FL 33701, Phone: (727) 767-8230, Fax: (727) 767-7786.
University of South Florida · USUniversity of Arizona · US

Funding

2/2-D-Cycloserine Augmentation of CBT for Pediatric OCDR01MH093402 · NIMH · MASSACHUSETTS GENERAL HOSPITAL · PI GELLER, DANIEL A · 2011 to 2014
$1.7M
1/2-D-Cycloserine Augmentation of CBT for Pediatric OCDR01MH093381 · NIMH · UNIVERSITY OF SOUTH FLORIDA · PI STORCH, ERIC A. · 2011 to 2014
$1.2M
NIMH NIH HHS R01 MH093381NIMH NIH HHS R01 MH093402
6 · The paper itself

Abstract

Variants of exposure therapy are effective for treating obsessive-compulsive and related disorders (OCRDs). However, significant numbers of patients do not respond adequately to exposure therapy resulting in continued distress and functional impairment. Therefore, novel approaches to augmenting exposure therapy are needed to adequately treat non- and partial-responders. Emerging research suggests that interventions that augment learning and memory processes associated with exposure therapy (i.e., extinction training) may display promise in enhancing treatment response in OCRDs. As the most studied example, d-cycloserine (DCS) is a relatively safe cognitive enhancer that appears to accelerate treatment gains associated with exposure therapy. This article reviews research on the use of DCS and other putative cognitive modifiers as they relate to the treatment (or prospective treatment) of obsessive-compulsive disorder and other OCRDs.

Indexed as

Brain-derived neurotrophic factorCognitive enhancerD-cycloserineGlucocorticoidsMemory reconsolidationObsessive-compulsive disorderYohimbine

Identifiers

PMID25383074
PMCPMC4223803
OpenAlexW2113289104

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.